Human Immunodeficiency Virus (HIV) Therapeutics Market Size

Human Immunodeficiency Virus Therapeutics Market Size

The global human immunodeficiency virus therapeutics market size valued at USD 39 billion in 2024 and is projected to exhibit 3.5% CAGR from 2025 to 2034. High incidence of HIV infections, advances in therapeutic treatment options, growing support through government initiatives and health programs, and favorable regulatory approvals are driving the revenue growth in the market.

Regulatory bodies, such as the U.S. FDA, are approving innovative HIV treatments, including approvals for patients with limited treatment options. These alternatives cater to patients who face difficulties with daily oral medication regimens. For instance, In December 2022, the U.S. FDA approved Sunlenca (lenacapavir), a novel antiretroviral medication. This approval addresses the needs of adult patients with human immunodeficiency virus type 1 (HIV-1) whose infections are resistant to, intolerant of, or unsafe with other available treatments.
 

Human immunodeficiency virus therapeutics encompass medical treatments designed to manage and control HIV infections. These therapies primarily involve antiretroviral drugs that inhibit viral replication, thereby preventing or delaying the progression to AIDS. The primary objectives of HIV treatment are to reduce the viral load to undetectable levels, maintain a robust immune system, and prevent virus transmission.